


**Genetics of
Inherited Sudden Death**




Barry London, MD PhD
Director, Division of Cardiovascular Medicine
Director, Abboud Cardiovascular Research Center
Professor of Medicine, Molecular Physiology & Biophysics
University of Iowa Carver College of Medicine


Mini Medical School 03/31/15

Disclosures: None


Clinical Case



ECG of a 15 Year Old Girl Who Fainted




Clinical Case




24 Hour ECG Recording Strips

Baseline



3:30 AM
Nightmare



Cardiac Arrhythmias



- Major cause of morbidity and mortality
- At least 250,000 sudden deaths per year in the United States
- Treatment is inadequate
- Most sudden death is associated with structural heart disease (MI, CHF)
- We have learned a lot from the rare genetic syndromes with simple inheritance (long QT & Brugada syndromes)

Inherited Arrhythmia Syndromes



- | | |
|------------------------------------|-----------|
| • Long QT Syndrome | 1:2500 |
| • Short QT Syndrome | very rare |
| • Brugada Syndrome | 1:5000 |
| • Early Repolarization Syndrome | unknown |
| • Catecholaminergic Polymorphic VT | rare |
| • Familial Atrial Fibrillation | rare |
| • Conduction Defects: Lev, Lenegre | rare |
| • WPW | very rare |

Inherited Cardiomyopathies With Arrhythmias




- | | |
|------------------------------------|-----------|
| • Hypertrophic Cardiomyopathy | 1:500 |
| • Dilated Cardiomyopathy | 1:500 (?) |
| • Arrhythmogenic RV Cardiomyopathy | rare |
| • LV Noncompaction | very rare |
| • Restrictive Cardiomyopathies | rare |

NORMAL

DILATED

HYPERTROPHIC

RV CARDIOMYOPATHY



Why Study Inherited Arrhythmia Syndromes?




- Identifying the gene and the mutation helps with the diagnosis and treatment of the families with the rare disorders
- We hope that the lessons learned about arrhythmia and sudden death can be applied to the more common causes of arrhythmia and sudden death

DNA and Genetics




- Everyone has ~3 billion base pairs of DNA on 23 chromosomes, 2 copies each
- DNA encodes ~30,000 genes, which are copied into RNA and code for proteins
- DNA, RNA, and proteins are further modified
- Inherited diseases result from mutations (mistakes) in the DNA
- Book analogy


Common Inheritance Patterns




Heart Cells are Batteries



The ECG Measures the Spread of Cardiac Electrical Activity



Electrical Activity Triggers Contraction in the Heart



Brugada Syndrome: Clinical Characteristics



- Rare, 1:5000
- Characterized by a right bundle branch block pattern and ST segment elevation in electrocardiogram (ECG) leads V₁-V₃ (Brugada & Brugada, 1992)
- ECG pattern can vary from day to day
- No structural heart disease
- Can cause fainting & sudden cardiac death
- More common in Southeast Asia (Bangungut, Pokkuri, Lai Tai, SUDS).

Brugada Syndrome: Clinical Characteristics



- Autosomal dominant inheritance pattern with variable penetrance
- Sodium channel blockers (e.g. procainamide, ajmaline) exacerbate the ECG findings and are used diagnostically (Brugada et al., 2000)
- Fevers exacerbate the ECG pattern & arrhythmias
- Associated with conduction disease
- Implantable Cardioverter Defibrillator (ICD) is only proven treatment

Brugada Syndrome: Genetics and Mechanism



- Autosomal dominant inheritance pattern with variable penetrance
- Mutations of the cardiac sodium (Na⁺) channel (SCN5A) that decrease inward cause ~20% of Brugada syndrome cases (Chen et al., 1998)
- Reduced inward sodium or calcium depolarizing currents in the right ventricle, where outward currents are large, lead to the ECG changes and arrhythmias (Antzelevitch, 1998)

Brugada Syndrome: Mechanism

Truncated Epicardial APs Phase 2 Reentry

AP: Endocardial, Epicardial, 30 mV, 100 ms

ECG: 1 mV, 100 ms

Phase 2 Reentry: 0-4, 0-3, 0-2, 0-1, 200 msec, 50 mV

Brugada Syndrome: Known Genetic Causes

Locus	Protein	Gene	Current	Chromosome
BRGDA1	Na _v 1.5	SCN5A	↓ I _{Na}	3p21
BRGDA2	GPD1-L	GPD1L	↓ I _{Na}	3p24
BRGDA3	Ca _v 1.2	CACNA1C	↓ I _{Ca}	12p13.3
BRGDA4	Ca _v β2	CACNB2B	↓ I _{Ca}	10p12
BRGDA5	Na _v β1	SCN1B	↓ I _{Na}	19q13
BRGDA6	MiRP2	KCNE3	↑ I _{to}	11q13.4
BRGDA7	Na _v β3	SCN3B	↓ I _{Na}	11q24.1
BRGDA8	HCN4	HCN4	?	15q24.1
BRGDA9	Kv4.3	KCND3	↑ I _{to}	1p13.2


Other Genes: MOG1, FGF12


Brugada Syndrome: FM Family


45 Year Old Man Who Fainted


Proband presented with syncope and got an AICD


1, 2, 3, 4















Brugada Syndrome: FN Family




GPD1-L Mutation Decreases Na⁺ Current

Na Current in HEK Cells

Current-Voltage Curves



The GPD1-L mutant leads to a 60% decrease in Na current



Inherited Sudden Death: Clinical Screening



- Who? All first degree relatives (or closest available) and all symptomatic blood relatives; then cascade screening
- How? History, Family History, ECG, Echocardiogram, +/- MRI, +/- Stress Test, +/- Drug Challenge
- Why? Treatments including follow-up, avoiding medications, avoiding competitive sports, medications, ICDs

Inherited Sudden Death: Genetic Screening



- Efficacy: LQTS (~60%), Brugada (~30%), CPVT (>50%), ARVD (~50%), HCM (>60%), DCM (>40%)
- Who to screen if mutation is not known? a definitively affected family member
- Who to screen if mutation known? all first degree relatives (or closest available) and all symptomatic blood relatives; then cascade screening

Inherited Sudden Death: Genetic Screening



- Advantages:
 - Carriers: Avoid drugs that exacerbate, exercise
 - Carriers: Potential to guide treatments
 - Asymptomatic Carriers: Therapies, Follow-up
 - Non-carrier of known mutation: Peace of mind
- Problems:
 - Cost: Variable coverage by insurance
 - Useless if definitive mutation is not found
 - Carriers: Can damage careers, insurability
 - Conclusions may be wrong

Acknowledgments



University of Iowa

Shengchuan Dai MD	Haider Mehdi PhD
Xiaodong Zhu PhD	Gina Morgan
Rebecca Gutmann RN BS	Jin-Young Yoon PhD
Kaikobad Irani MD PhD	Ajit Vikran PhD

University of Pittsburgh

Samir Saba MD	Indrani Halder PhD	Asma Navqi
Ryan Aleong MD	Marwan Refaat MD	Laurie Kerchner
Alaa Shalaby MD	Laurie Kerchner BS	Madhur Singh MD
Christopher Lewarchik PhD		

Emory University

Samuel Dudley MD PhD
Heather Bloom MD

Washington U. in St. Louis

Jeanne Nerbonne PhD

Mass General

Patrick Ellinor MD PhD

Ohio State

Raul Weiss MD

Mayo Clinic

Michael Ackerman MD PhD

Funded by NIH R01HL62300, R01HL77398, R01HL115955
